{"id":"W3159728738","doi":"10.1038/s41467-021-22582-6","title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lawson Health Research Institute; Université de Montréal; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development; National Cancer Institute; Stand Up To Cancer; Genentech; Foundation Medicine; Sierra Oncology; PharmaMar; AstraZeneca Australia; Eisai; Mateon Therapeutics; National Breast Cancer Foundation; BeiGene; Clovis Oncology; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; Regeneron Pharmaceuticals; Ludwig Institute for Cancer Research; Exelixis; Eli Lilly and Company; U.S. Department of Defense; Sanofi; GlaxoSmithKline; Ovarian Cancer Research Fund; Bristol-Myers Squibb; AstraZeneca; Pfizer; Ovarian Cancer Research Fund Alliance; Array BioPharma","keywords":"Cancer research; PARP inhibitor; Ovarian cancer; Medicine; Biomarker; Oncology; Homologous recombination; Biology; Bioinformatics; Cancer; Internal medicine; Poly ADP ribose polymerase; Genetics; Gene; Polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003480754,0.00008955796,0.0002746245,0.00006873037,0.00006773597,0.00001067632,0.00007563338,0.0001517414,0.000003712271],"category_scores_gemma":[0.0003904615,0.00008496536,0.00003477648,0.0001606506,0.0001293454,0.00002701168,0.00007786605,0.0002239703,1.205626e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008222536,"about_ca_system_score_gemma":0.0002282001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002825176,"about_ca_topic_score_gemma":0.006321067,"domain_scores_codex":[0.9990754,0.0002202935,0.0003098678,0.0002196931,0.00007311231,0.0001016899],"domain_scores_gemma":[0.9983811,0.0005706943,0.00007013238,0.0007239736,0.0001510266,0.0001030627],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03126003,0.003387146,0.7826131,0.0005660281,0.0006503023,0.00010869,0.007294796,0.000009659552,0.03391911,0.02328397,0.004140527,0.1127666],"study_design_scores_gemma":[0.01313654,0.001441367,0.7637515,0.001857364,0.0003480583,0.0000670819,0.0005302153,0.0009699998,0.01945961,0.001945751,0.1960961,0.0003964408],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9382378,0.04284758,0.00005006887,0.01798441,0.00006927269,0.0005698289,0.0001124047,0.000007986075,0.0001206841],"genre_scores_gemma":[0.977815,0.00830757,0.01280732,0.0006902544,0.00001603813,0.0002430672,0.000018246,0.00001085172,0.00009162414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1919556,"threshold_uncertainty_score":0.3527304,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06698202711603134,"score_gpt":0.4452275900725575,"score_spread":0.3782455629565262,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}